Interleukin 4 or cytokine antagonists? Time to change the search for novel psoriasis therapies

Dermatology

Volumn 221, Issue 1, 2010, Pages 27-29

  Röcken, Martin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 4; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; NONHUMAN; PLASMID; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

EID: 77955709285     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314153     Document Type: Editorial

References (22)

1. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009; 361: 496-509.
2. Luftl M, Degitz K, Plewig G, Rocken M: Psoralen bath plus UV-A therapy: possibilities and limitations. Arch Dermatol 1997; 133: 1597-1603.
3. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
4. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet Oncol 2007; 370: 263-271.
5. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
6. Kneilling M, Mailhammer R, Hultner L, Schonberger T, Fuchs K, Schaller M, Bukala D, Massberg S, Sander CA, Braumuller H, Eichner M, Maier KL, Hallmann R, Pichler BJ, Haubner R, Gawaz M, Pfeffer K, Biedermann T, Rocken M: Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood 2009;114: 1696-1706.
7. Ghoreschi K, Mrowietz U, Rocken M: A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003; 81: 471-480.
8. Altmeyer PJ, Matthes U, Pawlak F, et al: Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-981.
9. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-592.
10. Heidenreich R, Rocken M, Ghoreschi K: Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90: 232-248.
11. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Forster I, Huss R, Weber WA, Kneilling M, Rocken M: TNFR1 signaling and IFN- signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13: 507-518.
12. Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, Seegmuller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA, Rocken M: IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001; 2: 1054-1060.
13. Guenova E, Volz T, Sauer K, Kaesler S, Muller MR, Wolbing F, Chen K, Schwarzler C, Brossart P, Rocken M, Biedermann T: IL-4- mediated fine tuning of IL-12p70 production by human DC. Eur J Immunol 2008; 38: 3138-3149.
14. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Rocken M: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9: 40-46.
15. Martin R: Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases? Trends Pharmacol Sci 2003; 24: 613-616.
16. Zhang Y, Li J, Liu CY, Zjou X, Qiu J, Zhan Y, Huang N, Chen X, Li X, Wang Y, Yang H, Chen X, Kan B, Mao Y, Deng H, Yang L, Wen Y, Zhao X, Wei YQ: A novel transdermal plasmid-dimethylsufoxide delivery technique for treatment of psoriasis. Dermatology DOI: 10.1159/000314154.
17. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141-1146.
18. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, Shevach EM, Rocken M: Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994; 180: 1961-1966.
19. Biedermann T, Mailhammer R, Mai A, Sander C, Ogilvie A, Brombacher F, Maier K, Levine AD, Rocken M: Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigenspecific Th2 cells. Eur J Immunol 2001; 31: 1582-1591.
20. Ren X, Li J, Zhou X, Luo X, Huang N, Wang Y, Chen X, Wei Y: Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Dermatology 2009; 219: 232-238.
21. Leach MW, Rybak ME, Rosenblum IY: Safety evaluation of recombinant human interleukin- 4. II. Clinical studies. Clin Immunol Immunopathol 1997; 83: 12-14.
22. Breit S, Steinhoff M, Blaser K, Heusser CH, Sebald W, Levine AD, Rocken M: A strict requirement of interleukin-4 for interleukin-4 induction in antigen-stimulated human memory T cells. Eur J Immunol 1996; 26: 1860-1865.